Biswas, S., Srivastava, Y., & Hamadttu, A. (2026 Supplement 19). Comparative effectiveness of first-line ribociclib plus aromatase inhibitor versus palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer: A global real-world evidence study. Journal of Clinical Oncology, 44, 45-85.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Biswas, Shankar, Yashasvi Srivastava, and Ayman Hamadttu. "Comparative Effectiveness of First-line Ribociclib Plus Aromatase Inhibitor Versus Palbociclib Plus Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer: A Global Real-world Evidence Study."
Journal of Clinical Oncology 44 (2026 Supplement 19): 45-85.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Biswas, Shankar, et al. "Comparative Effectiveness of First-line Ribociclib Plus Aromatase Inhibitor Versus Palbociclib Plus Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer: A Global Real-world Evidence Study."
Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 45-85.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.